
News|Videos|June 11, 2019
Dr. Jason Westin on Combination Targeted Therapy Prior to Chemotherapy for DLBCL
Author(s)Jason Westin, MD
Cancer Network spoke with Jason Westin, MD, of MD Anderson Cancer Center, about the Smart Start trial, which showed that a combination of targeted therapy prior to chemotherapy proved to be effective in patients with DLBCL.
Advertisement
Cancer Network spoke with Jason Westin, MD, of MD Anderson Cancer Center, about the Smart Start trial, which showed that a combination of targeted therapy prior to chemotherapy proved to be effective in patients with DLBCL.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer
2
Combining a PCNA Inhibitor with KRAS-Targeting Agents in PDAC
3
Elranatamab Significantly Improves PFS in R/R Multiple Myeloma Trial
4
Targeting KRAS in Pancreatic Cancer: What is Daraxonrasib’s Mechanism of Action?
5
























































